Synmosa Biopharma (4114) — Cash Flow Reinvestment Rate
Synmosa Biopharma (4114) has a Cash Flow Reinvestment Rate of 5.31x as of December 2025, reinvesting NT$986.18 Million (capex NT$59.46 Million plus investments NT$926.72 Million) from operating cash flow of NT$185.72 Million. Check 4114 cash flow quality score to evaluate the quality of earnings relative to operating cash generation.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Synmosa Biopharma Cash Flow Reinvestment Rate (2015–2025)
Historical reinvestment intensity for Synmosa Biopharma across 9 annual periods. Explore Synmosa Biopharma (4114) long-term investment share to see how much of total assets are deployed in long-term investments.
Annual Cash Flow Reinvestment Rate for Synmosa Biopharma (2015–2025)
Year-by-year capital reinvestment analysis for Synmosa Biopharma. For live market cap and broader valuation context, see how much is Synmosa Biopharma worth.
| Year | Reinvestment Rate | Total Reinvested (TWD) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2025 | 1.64x | NT$676.44 Million | NT$411.57 Million | NT$281.13 Million | ▲ +294.7% |
| 2024 | 0.42x | NT$325.05 Million | NT$780.62 Million | NT$269.65 Million | ▼ -78.4% |
| 2023 | 1.93x | NT$987.64 Million | NT$511.93 Million | NT$269.77 Million | ▲ +437.5% |
| 2022 | 0.36x | NT$226.22 Million | NT$630.25 Million | NT$129.29 Million | ▲ +63.6% |
| 2021 | 0.22x | NT$97.47 Million | NT$444.29 Million | NT$93.06 Million | ▼ -77.2% |
| 2020 | 0.96x | NT$244.96 Million | NT$254.40 Million | NT$154.41 Million | ▼ -97.3% |
| 2018 | 35.49x | NT$567.76 Million | NT$16.00 Million | NT$314.43 Million | ▲ +473.8% |
| 2016 | 6.19x | NT$1.46 Billion | NT$236.48 Million | NT$423.92 Million | ▼ -66.2% |
| 2015 | 18.30x | NT$431.85 Million | NT$23.60 Million | NT$369.26 Million | — |